John C. Reed - 15 Aug 2026 Form 4 Insider Report for MADRIGAL PHARMACEUTICALS, INC. (MDGL)

Reporting relationship: Director
Issuer ticker: MDGL
Reported as of: 15 Aug 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 18 Aug 2026, 17:10:25 UTC
Prior SEC filing: 18 Aug 2026
Source filing: View source filing
Reporting owner signature: /s/ Mardi Dier, as Attorney-in-Fact

Key filing fact

John C. Reed filed Form 4 for MADRIGAL PHARMACEUTICALS, INC. (MDGL) on 18 Aug 2026.

Key facts

This page summarizes John C. Reed's Form 4 filing for MADRIGAL PHARMACEUTICALS, INC. (MDGL).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 18 Aug 2026, 17:10.

Change

Previous filing in this sequence was filed on 18 Aug 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001181561 Primary reporting owner

REED JOHN C

Relationship: Director
Address: C/O MADRIGAL PHARMACEUTICALS, INC., 1001 CONSHOHOCKEN STATE ROAD SUITE 2-350, WEST CONSHOHOCKEN
Signature: /s/ Mardi Dier, as Attorney-in-Fact
Signature date: 18 Aug 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

MDGL transaction

Common Stock

Award

Transaction value
Shares: +647
Change %
Price: $0.000000^*
Shares after: 647
Date: 15 Aug 2026
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

MDGL transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares: +1,078
Change %
Price: $0.000000^*
Shares after: 1,078
Date: 15 Aug 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 1,078
Exercise price: $507.56
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Represents a grant of restricted stock units which vest as to 50% of the shares on each of August 15, 2027 and August 15, 2028, provided the Reporting Person continues in service with the Issuer on each such date.

Footnote F2

The option vests as to 50% of the shares on the first anniversary of the date of grant (August 15, 2027), and, thereafter, 12.5% of the shares shall vest on the last day of each successive three-month period for four successive three-month periods, provided the Reporting Person continues in service with the Issuer on each such date.